Back to School: How biopharma can reboot drug development. Access exclusive analysis here
WYE was off $11.94 (24%) to $37.30 on 50.5 million shares on Tuesday after the NIH discontinued a trial that used
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury